+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Needle-Free Injectors Market Forecast, Trend Analysis & Opportunity Assessment 2021-2031

  • ID: 5509563
  • Report
  • January 2021
  • Region: Global
  • 250 Pages
  • Future Market Insights

FEATURED COMPANIES

  • Antares Pharma
  • Crossject
  • Ferring Pharmaceuticals
  • Gerresheimer AG
  • PenJet Corporation
  • Pfizer Inc.

A recent market study by this publisher on the Needle-Free Injectors market offers a global industry analysis for 2016-2020 and an opportunity assessment for 2021-2031. The report consists of a comprehensive assessment of the most important market dynamics. On conducting thorough research on the historical as well as current growth parameters of the Needle-Free Injectors market, growth prospects of the market are obtained with maximum precision.

The report features unique and salient factors that may make a huge impact on the development of the Needle-Free Injectors market during the forecast period. It can help market players modify their manufacturing and marketing strategies to envisage maximum growth in this market in the coming years.

The report provides detailed information about the current and future growth prospects of Needle-Free Injectors market in the most comprehensive way for better understanding of readers.


Key Segments of Needle-Free Injectors Market


This study on the Needle-Free Injectors market offers information divided into seven important segments - load, technology, delivery site, application, usage, end user and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.


Load

  • Liquid Injections
  • Powder Injections
  • Projectile Injections

Technology

  • Spring-loaded jet injector
  • Battery-powered jet injector
  • Gas-powered jet injector

Delivery Site

  • Intra dermal injectors
  • Intramuscular injectors
  • Subcutaneous injectors

Application

  • Drug Delivery
  • Vaccines
  • Cosmetic
  • Others

Usage

  • Reusable Needle Free Injectors
  • Disposable Needle Free Injectors

End User

  • Hospitals
  • Veterinary Hospitals
  • Speciality Clinics
  • Home Care Settings
  • Others

Region

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • MEA
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Antares Pharma
  • Crossject
  • Ferring Pharmaceuticals
  • Gerresheimer AG
  • PenJet Corporation
  • Pfizer Inc.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side and Supply Side Trends
1.3. Technology Roadmap
1.4. Analysis and Recommendations

2. Market Overview
2.1. Market Coverage/Taxonomy
2.2. Market Definition/Scope/Limitations
2.3. Inclusions and Exclusions

3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation/Development Trends

4. Market Background
4.1. Macro-Economic Factors
4.1.1. Global Healthcare Outlook
4.1.2. Per Capita Healthcare Expenditure Outlook
4.1.3. Increased Cancer Research Funding
4.2. Forecast Factors - Relevance & Impact
4.2.1. Key Players Historical Growth
4.2.2. Product Adoption Across Regions
4.2.3. Product Cost
4.2.4. Technological Advancements
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities

5. Market Context
5.1. Product Adoption Analysis
5.2. Key Strategies Followed by Manufacturers
5.3. Application & Technology Assessment
5.4. Regulatory Scenario
5.5. Advantage and Disadvantage
5.6. Limitations of Hypodermic Needles

6. COVID19 Crisis Analysis
6.1. Current COVID19 Statistics and Probable Future Impact
6.2. Current Gdp Projection and Probable Impact
6.3. Current Economic Projection as Compared to 2008 Financial Analysis
6.4. COVID19 and Impact Analysis
6.4.1. Revenue by Load
6.4.2. Revenue by End-user
6.4.3. Revenue by Region
6.5. 2021 Market Scenario
6.6. Recovery Scenario - Short Term, Midterm and Long Term Impact

7. Global Needle-Free Injectors Market Demand (In Value or Size in US Mn) Analysis 2016-2020 and Forecast, 2021-2031
7.1. Historical Market Value (Us$ Mn) Analysis, 2016-2020
7.2. Current and Future Market Value (Us$ Mn) Projections, 2021-2031
7.2.1. Y-O-Y Growth Trend Analysis
7.2.2. Opportunity Analysis, 2021-2031

8. Global Needle-Free Injectors Market Analysis 2016-2020 and Forecast 2021-2031, by Load
8.1. Introduction/Key Findings
8.2. Historical Market Size (Us$ Mn) and Volume (Units) Analysis by Load, 2016-2020
8.3. Current and Future Market Size (Us$ Mn) and Volume (Units) Analysis and Forecast by Load, 2021-2031
8.3.1. Liquid Injections
8.3.2. Powder Injections
8.3.3. Projectile Injections
8.4. Market Attractiveness Analysis by Load

9. Global Needle-Free Injectors Market Analysis 2016-2020 and Forecast 2021-2031, by Technology
9.1. Introduction/Key Findings
9.2. Historical Market Size (Us$ Mn) Analysis by Technology, 2016-2020
9.3. Current and Future Market Size (Us$ Mn) Analysis and Forecast by Technology, 2021-2031
9.3.1. Spring-Loaded Jet Injector
9.3.2. Battery-Powered Jet Injector
9.3.3. Gas-Powered Jet Injector
9.4. Market Attractiveness Analysis by Technology

10. Global Needle-Free Injectors Market Analysis 2016-2020 and Forecast 2021-2031, by Delivery Site
10.1. Introduction/Key Findings
10.2. Historical Market Size (Us$ Mn) Analysis by Delivery Site, 2016-2020
10.3. Current and Future Market Size (Us$ Mn) Analysis and Forecast by Delivery Site, 2021-2031
10.3.1. Intra Dermal Injectors
10.3.2. Intramuscular Injectors
10.3.3. Subcutaneous Injectors

11. Global Needle-Free Injectors Market Analysis 2016-2020 and Forecast 2021-2031, by Application
11.1. Introduction/Key Findings
11.2. Historical Market Size (Us$ Mn) Analysis by Application, 2016-2020
11.3. Current and Future Market Size (Us$ Mn) Analysis and Forecast by Application, 2021-2031
11.3.1. Drug Delivery
11.3.2. Vaccines
11.3.3. Cosmetic
11.3.4. Others
11.4. Market Attractiveness Analysis by Application

12. Global Needle-Free Injectors Market Analysis 2016-2020 and Forecast 2021-2031, by Usage
12.1. Introduction/Key Findings
12.2. Historical Market Size (Us$ Mn) Analysis by Usage, 2016-2020
12.3. Current and Future Market Size (Us$ Mn) Analysis and Forecast by Usage, 2021-2031
12.3.1. Reusable Needle Free Injectors
12.3.2. Disposable Needle Free Injectors
12.4. Market Attractiveness Analysis by Usage

13. Global Needle-Free Injectors Market Analysis 2016-2020 and Forecast 2021-2031, by End-user
13.1. Introduction/Key Findings
13.2. Historical Market Size (Us$ Mn) Analysis by End-user, 2016-2020
13.3. Current and Future Market Size (Us$ Mn) Analysis and Forecast by End-user, 2021-2031
13.3.1. Hospitals
13.3.2. Veterinary Hospitals
13.3.3. Speciality Clinics
13.3.4. Home Care Settings
13.3.5. Others
13.4. Market Attractiveness Analysis by End-user

14. Global Needle-Free Injectors Market Analysis 2016-2020 and Forecast 2021-2031, by Region
14.1. Introduction
14.2. Historical Needle-Free Injectors Market (Us$ Mn) and Volume (Units) Analysis by Region, 2015 - 2019
14.3. Current Needle-Free Injectors Market (Us$ Mn) and Volume (Units) Analysis and Forecast by Region, 2020 - 2030
14.3.1. North America
14.3.2. Latin America
14.3.3. Europe
14.3.4. East Asia
14.3.5. South Asia
14.3.6. Oceania
14.3.7. Middle East and Africa (Mea)
14.4. Market Attractiveness Analysis by Region

15. North America Needle-Free Injectors Market Analysis 2016-2020 and Forecast 2021-2031
15.1. Introduction
15.2. Historical Market Value (Us$ Mn) Trend Analysis by Market Taxonomy, 2016-2020
15.3. Market Value (Us$ Mn) Forecast by Market Taxonomy, 2021-2031
15.3.1. by Country
15.3.1.1. U.S.
15.3.1.2. Canada
15.3.2. by Load
15.3.3. by Technology
15.3.4. by Delivery Site
15.3.5. by Application
15.3.6. by Usage
15.3.7. by End-user
15.4. Market Attractiveness Analysis
15.5. Key Market Participants - Intensity Mapping

16. Latin America Needle-Free Injectors Market Analysis 2016-2020 and Forecast 2021-2031
16.1. Introduction
16.2. Historical Market Value (Us$ Mn) Trend Analysis by Market Taxonomy, 2015 - 2019
16.3. Market Value (Us$ Mn) Forecast by Market Taxonomy, 2021-2031
16.3.1. by Country
16.3.1.1. Brazil
16.3.1.2. Mexico
16.3.1.3. Argentina
16.3.1.4. Rest of Latin America
16.3.2. by Load
16.3.3. by Technology
16.3.4. by Delivery Site
16.3.5. by Application
16.3.6. by Usage
16.3.7. by End-user
16.4. Market Attractiveness Analysis
16.5. Key Market Participants - Intensity Mapping

17. Europe Needle-Free Injectors Market Analysis 2016-2020 and Forecast 2021-2031
17.1. Introduction
17.2. Historical Market Value (Us$ Mn) Trend Analysis by Market Taxonomy, 2016-2020
17.3. Market Value (Us$ Mn) Forecast by Market Taxonomy2021-2031
17.3.1. by Country
17.3.1.1. Germany
17.3.1.2. Italy
17.3.1.3. France
17.3.1.4. U.K.
17.3.1.5. Spain
17.3.1.6. Russia
17.3.1.7. Rest of Europe
17.3.2. by Load
17.3.3. by Technology
17.3.4. by Delivery Site
17.3.5. by Application
17.3.6. by Usage
17.3.7. by End-user
17.4. Market Attractiveness Analysis
17.5. Key Market Participants - Intensity Mapping

18. South Asia Needle-Free Injectors Market Analysis 2016-2020 and Forecast 2021-2031
18.1. Introduction
18.2. Historical Market Value (Us$ Mn) Trend Analysis by Market Taxonomy, 2016-2020
18.3. Market Value (Us$ Mn) Forecast by Market Taxonomy2021-2031
18.3.1. by Country
18.3.1.1. India
18.3.1.2. Thailand
18.3.1.3. Indonesia
18.3.1.4. Malaysia
18.3.1.5. Rest of South Asia
18.3.2. by Load
18.3.3. by Technology
18.3.4. by Delivery Site
18.3.5. by Application
18.3.6. by Usage
18.3.7. by End-user
18.4. Market Attractiveness Analysis
18.5. Key Market Participants - Intensity Mapping

19. East Asia Needle-Free Injectors Market Analysis 2016-2020 and Forecast 2021-2031
19.1. Introduction
19.2. Historical Market Value (Us$ Mn) Trend Analysis by Market Taxonomy, 2016-2020
19.3. Market Value (Us$ Mn) Forecast by Market Taxonomy, 2021-2031
19.3.1. by Country
19.3.1.1. China
19.3.1.2. Japan
19.3.1.3. South Korea
19.3.2. by Load
19.3.3. by Technology
19.3.4. by Delivery Site
19.3.5. by Application
19.3.6. by Usage
19.3.7. by End-user
19.4. Market Attractiveness Analysis
19.5. Key Market Participants - Intensity Mapping

20. Oceania Needle-Free Injectors Market Analysis 2016-2020 and Forecast 2021-2031
20.1. Introduction
20.2. Historical Market Value (Us$ Mn) Trend Analysis by Market Taxonomy, 2016-2020
20.3. Market Value (Us$ Mn) Forecast by Market Taxonomy, 2021-2031
20.3.1. by Country
20.3.1.1. Australia
20.3.1.2. New Zealand
20.3.2. by Load
20.3.3. by Technology
20.3.4. by Delivery Site
20.3.5. by Application
20.3.6. by Usage
20.3.7. by End-user
20.4. Market Attractiveness Analysis
20.5. Key Market Participants - Intensity Mapping

21. Middle East and Africa Needle-Free Injectors Market Analysis 2016-2020 and Forecast 2021-2031
21.1. Introduction
21.2. Historical Market Value (Us$ Mn) Trend Analysis by Value Taxonomy, 2016-2020
21.3. Market Delivery Site (Us$ Mn) Forecast by Market Taxonomy, 2021-2031
21.3.1. by Country
21.3.1.1. Gcc Countries
21.3.1.2. Turkey
21.3.1.3. South Africa
21.3.1.4. Rest of Middle East and Africa
21.3.2. by Load
21.3.3. by Technology
21.3.4. by Delivery Site
21.3.5. by Application
21.3.6. by Usage
21.3.7. by End-user
21.4. Market Attractiveness Analysis

22. Key & Emerging Countries Needle-Free Injectors Market Analysis 2016-2020 and Forecast 2021-2031
22.1. U.S. Needle-Free Injectors Market Analysis
22.1.1. by Load
22.1.2. by Technology
22.1.3. by Delivery Site
22.1.4. by Application
22.1.5. by Usage
22.1.6. by End-user
22.2. Canada Needle-Free Injectors Market Analysis
22.2.1. by Load
22.2.2. by Technology
22.2.3. by Delivery Site
22.2.4. by Application
22.2.5. by Usage
22.2.6. by End-user
22.3. Brazil Needle-Free Injectors Market Analysis
22.3.1. by Load
22.3.2. by Technology
22.3.3. by Delivery Site
22.3.4. by Application
22.3.5. by Usage
22.3.6. by End-user
22.4. Mexico Needle-Free Injectors Market Analysis
22.4.1. by Load
22.4.2. by Technology
22.4.3. by Delivery Site
22.4.4. by Application
22.4.5. by Usage
22.4.6. by End-user
22.5. U.K. Needle-Free Injectors Market Analysis
22.5.1. by Load
22.5.2. by Technology
22.5.3. by Delivery Site
22.5.4. by Application
22.5.5. by Usage
22.5.6. by End-user
22.6. Germany Needle-Free Injectors Market Analysis
22.6.1. by Load
22.6.2. by Technology
22.6.3. by Delivery Site
22.6.4. by Application
22.6.5. by Usage
22.6.6. by End-user
22.7. France Needle-Free Injectors Market Analysis
22.7.1. by Load
22.7.2. by Technology
22.7.3. by Delivery Site
22.7.4. by Application
22.7.5. by Usage
22.7.6. by End-user
22.8. Italy Needle-Free Injectors Market Analysis
22.8.1. by Load
22.8.2. by Technology
22.8.3. by Delivery Site
22.8.4. by Application
22.8.5. by Usage
22.8.6. by End-user
22.9. Spain Needle-Free Injectors Market Analysis
22.9.1. by Load
22.9.2. by Technology
22.9.3. by Delivery Site
22.9.4. by Application
22.9.5. by Usage
22.9.6. by End-user
22.10. Russia Needle-Free Injectors Market Analysis
22.10.1. by Load
22.10.2. by Technology
22.10.3. by Delivery Site
22.10.4. by Application
22.10.5. by Usage
22.10.6. by End-user
22.11. China Needle-Free Injectors Market Analysis
22.11.1. by Load
22.11.2. by Technology
22.11.3. by Delivery Site
22.11.4. by Application
22.11.5. by Usage
22.11.6. by End-user
22.12. Japan Needle-Free Injectors Market Analysis
22.12.1. by Load
22.12.2. by Technology
22.12.3. by Delivery Site
22.12.4. by Application
22.12.5. by Usage
22.12.6. by End-user
22.13. South Korea Needle-Free Injectors Market Analysis
22.13.1. by Load
22.13.2. by Technology
22.13.3. by Delivery Site
22.13.4. by Application
22.13.5. by Usage
22.13.6. by End-user
22.14. Malaysia Needle-Free Injectors Market Analysis
22.14.1. by Load
22.14.2. by Technology
22.14.3. by Delivery Site
22.14.4. by Application
22.14.5. by Usage
22.14.6. by End-user
22.15. India Needle-Free Injectors Market Analysis
22.15.1. by Load
22.15.2. by Technology
22.15.3. by Delivery Site
22.15.4. by Application
22.15.5. by Usage
22.15.6. by End-user
22.16. Indonesia Needle-Free Injectors Market Analysis
22.16.1. by Load
22.16.2. by Technology
22.16.3. by Delivery Site
22.16.4. by Application
22.16.5. by Usage
22.16.6. by End-user
22.17. Australia Needle-Free Injectors Market Analysis
22.17.1. by Load
22.17.2. by Technology
22.17.3. by Delivery Site
22.17.4. by Application
22.17.5. by Usage
22.17.6. by End-user
22.18. New Zealand Needle-Free Injectors Market Analysis
22.18.1. by Load
22.18.2. by Technology
22.18.3. by Delivery Site
22.18.4. by Application
22.18.5. by Usage
22.18.6. by End-user
22.19. Gcc Countries Needle-Free Injectors Market Analysis
22.19.1. by Load
22.19.2. by Technology
22.19.3. by Delivery Site
22.19.4. by Application
22.19.5. by Usage
22.19.6. by End-user
22.20. Turkey Needle-Free Injectors Market Analysis
22.20.1. by Load
22.20.2. by Technology
22.20.3. by Delivery Site
22.20.4. by Application
22.20.5. by Usage
22.20.6. by End-user
22.21. South Africa Needle-Free Injectors Market Analysis
22.21.1. by Load
22.21.2. by Technology
22.21.3. by Delivery Site
22.21.4. by Application
22.21.5. by Usage
22.21.6. by End-user

23. Competition Analysis
23.1. Competition Dashboard
23.2. Competition Benchmarking
23.3. Competition Deep Dive (Tentative List)
23.3.1. Asts Enterprises (Aunt) Pty Ltd
23.3.1.1. Overview
23.3.1.2. Product Portfolio
23.3.1.3. Profitability by Market Segments (Product/Channel/Regional)
23.3.1.4. Sales Footprint
23.3.1.5. Strategy Overview
23.3.1.5.1. Marketing Strategy
23.3.1.5.2. Product Strategy
23.3.1.5.3. Channel Strategy
23.3.2. Weston Medical
23.3.2.1. Overview
23.3.2.2. Product Portfolio
23.3.2.3. Profitability by Market Segments (Product/Channel/Regional)
23.3.2.4. Sales Footprint
23.3.2.5. Strategy Overview
23.3.2.5.1. Marketing Strategy
23.3.2.5.2. Product Strategy
23.3.2.5.3. Channel Strategy
23.3.3. Pharmajet
23.3.3.1. Overview
23.3.3.2. Product Portfolio
23.3.3.3. Profitability by Market Segments (Product/Channel/Regional)
23.3.3.4. Sales Footprint
23.3.3.5. Strategy Overview
23.3.3.5.1. Marketing Strategy
23.3.3.5.2. Product Strategy
23.3.3.5.3. Channel Strategy
23.3.4. Crossject
23.3.4.1. Overview
23.3.4.2. Product Portfolio
23.3.4.3. Profitability by Market Segments (Product/Channel/Regional)
23.3.4.4. Sales Footprint
23.3.4.5. Strategy Overview
23.3.4.5.1. Marketing Strategy
23.3.4.5.2. Product Strategy
23.3.4.5.3. Channel Strategy
23.3.5. Penjet® Corporation
23.3.5.1. Overview
23.3.5.2. Product Portfolio
23.3.5.3. Profitability by Market Segments (Product/Channel/Regional)
23.3.5.4. Sales Footprint
23.3.5.5. Strategy Overview
23.3.5.5.1. Marketing Strategy
23.3.5.5.2. Product Strategy
23.3.5.5.3. Channel Strategy
23.3.6. Caretek Medical
23.3.6.1. Overview
23.3.6.2. Product Portfolio
23.3.6.3. Profitability by Market Segments (Product/Channel/Regional)
23.3.6.4. Sales Footprint
23.3.6.5. Strategy Overview
23.3.6.5.1. Marketing Strategy
23.3.6.5.2. Product Strategy
23.3.6.5.3. Channel Strategy
23.3.7. Pfizer
23.3.7.1. Overview
23.3.7.2. Product Portfolio
23.3.7.3. Profitability by Market Segments (Product/Channel/Regional)
23.3.7.4. Sales Footprint
23.3.7.5. Strategy Overview
23.3.7.5.1. Marketing Strategy
23.3.7.5.2. Product Strategy
23.3.7.5.3. Channel Strategy
23.3.8. Antares Pharma, Inc.
23.3.8.1. Overview
23.3.8.2. Product Portfolio
23.3.8.3. Profitability by Market Segments (Product/Channel/Regional)
23.3.8.4. Sales Footprint
23.3.8.5. Strategy Overview
23.3.8.5.1. Marketing Strategy
23.3.8.5.2. Product Strategy
23.3.8.5.3. Channel Strategy
23.3.9. Injexuk
23.3.9.1. Overview
23.3.9.2. Product Portfolio
23.3.9.3. Profitability by Market Segments (Product/Channel/Regional)
23.3.9.4. Sales Footprint
23.3.9.5. Strategy Overview
23.3.9.5.1. Marketing Strategy
23.3.9.5.2. Product Strategy
23.3.9.5.3. Channel Strategy
23.3.10. Gaungzhou Medsinglong Medical Equipment Company Ltd.
23.3.10.1. Overview
23.3.10.2. Product Portfolio
23.3.10.3. Profitability by Market Segments (Product/Channel/Regional)
23.3.10.4. Sales Footprint
23.3.10.5. Strategy Overview
23.3.10.5.1. Marketing Strategy
23.3.10.5.2. Product Strategy
23.3.10.5.3. Channel Strategy
23.3.11. Zogenix
23.3.11.1. Overview
23.3.11.2. Product Portfolio
23.3.11.3. Profitability by Market Segments (Product/Channel/Regional)
23.3.11.4. Sales Footprint
23.3.11.5. Strategy Overview
23.3.11.5.1. Marketing Strategy
23.3.11.5.2. Product Strategy
23.3.11.5.3. Channel Strategy
23.3.12. D'antonio Consultants International, Inc.
23.3.12.1. Overview
23.3.12.2. Product Portfolio
23.3.12.3. Profitability by Market Segments (Product/Channel/Regional)
23.3.12.4. Sales Footprint
23.3.12.5. Strategy Overview
23.3.12.5.1. Marketing Strategy
23.3.12.5.2. Product Strategy
23.3.12.5.3. Channel Strategy
23.3.13. Acushot Needle Free
23.3.13.1. Overview
23.3.13.2. Product Portfolio
23.3.13.3. Profitability by Market Segments (Product/Channel/Regional)
23.3.13.4. Sales Footprint
23.3.13.5. Strategy Overview
23.3.13.5.1. Marketing Strategy
23.3.13.5.2. Product Strategy
23.3.13.5.3. Channel Strategy
23.3.14. Insujet™
23.3.14.1. Overview
23.3.14.2. Product Portfolio
23.3.14.3. Profitability by Market Segments (Product/Channel/Regional)
23.3.14.4. Sales Footprint
23.3.14.5. Strategy Overview
23.3.14.5.1. Marketing Strategy
23.3.14.5.2. Product Strategy
23.3.14.5.3. Channel Strategy
23.3.15. Qs Medical Technology Co., Ltd
23.3.15.1. Overview
23.3.15.2. Product Portfolio
23.3.15.3. Profitability by Market Segments (Product/Channel/Regional)
23.3.15.4. Sales Footprint
23.3.15.5. Strategy Overview
23.3.15.5.1. Marketing Strategy
23.3.15.5.2. Product Strategy
23.3.15.5.3. Channel Strategy
23.3.16. Mika Medical Co.
23.3.16.1. Overview
23.3.16.2. Product Portfolio
23.3.16.3. Profitability by Market Segments (Product/Channel/Regional)
23.3.16.4. Sales Footprint
23.3.16.5. Strategy Overview
23.3.16.5.1. Marketing Strategy
23.3.16.5.2. Product Strategy
23.3.16.5.3. Channel Strategy

24. Assumptions and Acronyms Used

25. Research Methodology
Note: Product cover images may vary from those shown
  • Gerresheimer AG
  • Pfizer Inc.
  • Antares Pharma
  • CSL Limited (Seqirus UK Limited)
  • Crossject
  • Portal Instruments
  • Ferring Pharmaceuticals
  • PharmaJet Inc.
  • PenJet Corporation
Note: Product cover images may vary from those shown